Pasadena, California 91105


Purpose:

This study is designed to evaluate the analgesic safety and efficacy of study drug (AP0302) applied topically every 6 hours as compared to a vehicle, in subjects experiencing delayed onset muscle soreness.


Study summary:

The purpose of this study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel 5% in reducing pain/soreness associated with delayed onset muscle soreness (DOMS).


Criteria:

Inclusion Criteria: - no clinically significant medical conditions - BMI between 18-30 - negative drug, alcohol, pregnancy screens - other protocol-defined inclusion criteria may apply Exclusion Criteria: - no upper extremity workout in last 6 months - no job requiring heavy lifting - history of muscle disorders - allergy or intolerance to study drug - history of recent pain medication use - other protocol-defined exclusion criteria may apply


NCT ID:

NCT02324985


Primary Contact:

Principal Investigator
Sonia Singla, DO
Lotus Clinical Research

Kenneth M Corroon, Chief Executive Officer
Email: kcorroon@aponialabs.com


Backup Contact:

N/A


Location Contact:

Pasadena, California 91105
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.